Compounds > nicainoprol
Page last updated: 2024-12-06

nicainoprol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID71147
CHEMBL ID2106788
SCHEMBL ID1816282
MeSH IDM0137790

Synonyms (37)

Synonym
nicainoprol
cas-924
ru-42924
[8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2h-quinolin-1-yl]-pyridin-3-ylmethanone
76252-06-7
1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-nicotinoylquinoline
(+-)-1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-nicotinoylquinoline
nicainoprolum [inn-latin]
1ua960p80h ,
1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-(3-pyridylcarbonyl)quinoline
unii-1ua960p80h
einecs 278-403-8
nicainoprolum
nicainoprol [inn]
CHEMBL2106788
methanone, (3,4-dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-1(2h)-quinolinyl)-3-pyridinyl-
(+/-)-1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-nicotinoylquinoline
quinoline, 1,2,3,4-tetrahydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-1-(3-pyridinylcarbonyl)-
AUIHHZBJBKRDIE-UHFFFAOYSA-N
1-nicotinoyl-8-[3-isopropylamino-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinoline
SCHEMBL1816282
1,2,3,4-tetrahydro-8-[2-hydroxy-3-(isopropylamino)propoxy]-1-(3-pyridylcarbonyl)quinoline
HY-100572
CS-6088
EX-A1211
AKOS027378523
nicainoprolhe
ZB0028
(8-(2-hydroxy-3-(isopropylamino)propoxy)-3,4-dihydroquinolin-1(2h)-yl)(pyridin-3-yl)methanone
BS-17524
BCP30068
cas-924; ru-42924; cas924; ru42924; cas 924; ru 42924
Q27252903
D83374
BDA25206
DTXSID10868395
AC-36833

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (75.00)18.7374
1990's3 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (23.08%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9810aromatic ether;
nitrile;
polyether;
tertiary amino compound
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		1.9810monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		1.9810benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		1.9810naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		1.971011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Metabolic Acidosis
[description not available]		01.9810
Anoxemia
[description not available]		01.9810
Hyperpotassemia
[description not available]		01.9810
Acidosis
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.		01.9810
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		01.9810
Hyperkalemia
Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)		01.9810
Chronic Illness
[description not available]		03.3611
Arrhythmia
[description not available]		04.4551
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		04.4551
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.3611
Atrioventricular Nodal Reentrant Tachycardia
[description not available]		03.3611
Tachycardia, Supraventricular
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.		03.3611
Coronary Heart Disease
[description not available]		01.9710
Cardiovascular Stroke
[description not available]		01.9710
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9710
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		01.9710
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		01.9710